Page last updated: 2024-09-05

sb 203580 and sulforaphane

sb 203580 has been researched along with sulforaphane in 1 studies

Compound Research Comparison

Studies
(sb 203580)
Trials
(sb 203580)
Recent Studies (post-2010)
(sb 203580)
Studies
(sulforaphane)
Trials
(sulforaphane)
Recent Studies (post-2010) (sulforaphane)
3,48941,1371,754651,317

Protein Interaction Comparison

ProteinTaxonomysb 203580 (IC50)sulforaphane (IC50)
Epidermal growth factor receptorHomo sapiens (human)9
Macrophage migration inhibitory factorHomo sapiens (human)2.2
Nitric oxide synthase, inducibleMus musculus (house mouse)0.4

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fahl, WE; Kong, AN; Lei, W; Mandlekar, S; Tan, TH; Yu, R1

Other Studies

1 other study(ies) available for sb 203580 and sulforaphane

ArticleYear
p38 mitogen-activated protein kinase negatively regulates the induction of phase II drug-metabolizing enzymes that detoxify carcinogens.
    The Journal of biological chemistry, 2000, Jan-28, Volume: 275, Issue:4

    Topics: Animals; Antioxidants; beta-Naphthoflavone; Butylated Hydroxyanisole; Carcinogens; Enzyme Activation; Enzyme Induction; Gene Expression Regulation, Enzymologic; Genes, Reporter; Humans; Hydroquinones; Imidazoles; Inactivation, Metabolic; Isothiocyanates; Kinetics; MAP Kinase Kinase 3; Mice; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; NAD(P)H Dehydrogenase (Quinone); p38 Mitogen-Activated Protein Kinases; Protein-Tyrosine Kinases; Pyridines; Sulfoxides; Thiocyanates; Tumor Cells, Cultured

2000